Table 3.
Concentration (mg/L) | 24 h mortality (%) | 48 h mortality (%) | 72 h mortality (%) |
Chlorantraniliprole/Penoxsulam | |||
0 (0/0) | 0.0±0.0d | 0.0±0.0d | 0.0±0.0d |
5.62 (4.01/1.61) | 0.0±0.0d | 0.0±0.0d | 23.3±5.8c |
6.17 (4.41/1.76) | 13.3±5.8c | 30.0±0.0c | 63.3±5.8b |
6.76 (4.83/1.93) | 20.0±0.0c | 46.7±5.8b | 86.7±5.8a |
7.41 (5.29/2.12) | 83.3±5.8b | 90.0±10.0a | 100.0±0.0a |
8.13 (5.81/2.32) | 93.3±5.8ab | 100.0±0.0a | |
8.91 (6.36/2.55) | 100.0±0.0a | ||
One-way ANOVA | F6, 14=437.667 | F5, 11=203.856 | F4, 9=215.679 |
Chlorantraniliprole/Flubendiamide-abamectin | |||
0 (0/0) | 0.0±0.0d | 0.0±0.0d | 0.0±0.0b |
2.04 (2.027/0.013) | 0.0±0.0d | 0.0±0.0d | 23.3±25.2b |
2.19 (2.176/0.014) | 0.0±0.0d | 23.3±5.8cd | 60.0±0.0a |
2.34 (2.325/0.015) | 36.7±30.6cd | 56.7±25.2bc | 80.0±10.0a |
2.51 (2.494/0.016) | 60.0±17.3bc | 80.0±20.0ab | 90.0±0.0a |
2.69 (2.672/0.018) | 86.7±5.8ab | 100.0±0.0a | |
2.88 (2.860/0.019) | 100.0±0.0a | ||
One-way ANOVA | F6, 14=28.360 | F5, 12=30.000 | F4, 9=24.191 |
Penoxsulam/Flubendiamide-abamectin | |||
0 (0/0) | 0.0±0.0e | 0.0±0.0d | 0.0±0.0e |
0.95 (0.935/0.015) | 0.0±0.0e | 0.0±0.0d | 13.3±5.8de |
1.02 (1.004/0.016) | 10.0±10.0de | 26.7±25.2cd | 36.7±23.1cd |
1.09 (1.073/0.017) | 36.7±15.3cd | 56.7±5.8bc | 63.3±5.8bc |
1.17 (1.151/0.019) | 63.3±25.2bc | 83.3±5.8ab | 90.0±0.0ab |
1.25 (1.230/0.020) | 83.3±5.8ab | 90.0±0.0a | 100.0±0.0a |
1.34( 1.319/0.021) | 100.0±0.0a | ||
One-way ANOVA | F6, 14=35.378 | F5, 12=41.076 | F5, 12=49.789 |
*P < 0.001; Types with different superscripts differ significantly (Tukey's test, α=0.05, a > b > c > d > e); NS: not significant.